EMEA-001045-PIP02-18
Key facts
| Invented name |
Kevzara
|
| Active substance |
sarilumab
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0335/2018
|
| PIP number |
EMEA-001045-PIP02-18
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of vasculitides
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Sanofi-aventis recherche et développement
Tel. +33 169745695 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|